Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor
- 4 February 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (5), 747-753
- https://doi.org/10.1016/j.jcf.2020.12.023
Abstract
No abstract availableKeywords
Funding Information
- European Commission (603038)
This publication has 23 references indexed in Scilit:
- CORK Study in Cystic FibrosisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2017
- Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogensInternational Journal of Antimicrobial Agents, 2017
- Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokersThorax, 2016
- Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D MutationPLOS ONE, 2015
- Cystic fibrosis genetics: from molecular understanding to clinical applicationNature Reviews Genetics, 2014
- Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Biogeochemical Forces Shape the Composition and Physiology of Polymicrobial Communities in the Cystic Fibrosis LungmBio, 2014
- Antibacterial properties of the CFTR potentiator ivacaftorJournal of Cystic Fibrosis, 2014
- Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D- CFTR mutation and preserved spirometry: a randomised controlled trialThe Lancet Respiratory Medicine, 2013
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011